Genetic and Phenotypic Profiling of Single Living Circulating Tumor Cells from Patients with Microfluidics
Zaizai Dong,Yusen Wang,Gaolian Xu,Bing Liu,Yang Wang,Julien Reboud,Pawel Jajesniak,Shi Yan,Pingchuan Ma,Feng Liu,Yuhao Zhou,Zhiyuan Jin,Kuan Yang,Zhaocun Huang,Minglei Zhuo,Bo Jia,Jian Fang,Panpan Zhang,Nan Wu,Mingzhu Yang,Jonathan M. Cooper,Lingqian Chang
DOI: https://doi.org/10.1073/pnas.2315168121
2024-01-01
Abstract:Accurate prediction of the efficacy of immunotherapy for cancer patients through the characterization of both genetic and phenotypic heterogeneity in individual patient cells holds great promise in informing targeted treatments, and ultimately in improving care pathways and clinical outcomes. Here, we describe the nanoplatform for interrogating living cell host - gene and (micro - )environment (NICHE) relationships, that integrates micro - and nanofluidics to enable highly efficient capture of circulating tumor cells (CTCs) from blood samples. The platform uses a unique nanopore - enhanced electrodelivery system that efficiently and rapidly integrates stable multichannel fluorescence probes into living CTCs for in situ quantification of target gene expression, while on - chip coculturing of CTCs with immune cells allows for the real - time correlative quantification of their phenotypic heterogeneities in response to immune checkpoint inhibitors (ICI). The NICHE microfluidic device provides a unique ability to perform both gene expression and phenotypic analysis on the same single cells in situ, allowing us to generate a predictive index for screening patients who could benefit from ICI. This index, which simultaneously integrates the heterogeneity of single cellular responses for both gene expression and phenotype, was validated by clinically tracing 80 non-small cell lung cancer patients, demonstrating significantly higher AUC (area under the curve) (0.906) than current clinical reference for immunotherapy prediction.